← Oncology Approval Tracker

FDA DECISION ·

Komzifti

ziftomenib · Kura Oncology

FDA approvalNew therapyAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory AML with a susceptible NPM1 mutation and no satisfactory alternative treatment options.

LAMPGEN ANALYSIS

Why it matters

This menin inhibitor adds an adult option in relapsed or refractory NPM1-mutated AML.

What research teams should watch

Document actionable NPM1 status and establish a site escalation plan for suspected differentiation syndrome.

PRIMARY RECORDS

Sources